Join Growin Stock Community!

Nuvectis pharma, inc.NVCT.US Overview

US StockHealthcare
(No presentation for NVCT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NVCT AI Insights

NVCT Overall Performance

NVCT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NVCT Recent Performance

-0.68%

Nuvectis pharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NVCT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NVCT Key Information

NVCT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NVCT Profile

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Price of NVCT

NVCT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NVCT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.86
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.86
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NVCT's latest earnings report released?

    The most recent financial report for Nuvectis pharma, inc. (NVCT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NVCT's short-term business performance and financial health. For the latest updates on NVCT's earnings releases, visit this page regularly.

  • How much cash does NVCT have?

    At the end of the period, Nuvectis pharma, inc. (NVCT) held Total Cash and Cash Equivalents of 31.63M, accounting for 1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NVCT's EPS continuing to grow?

    According to the past four quarterly reports, Nuvectis pharma, inc. (NVCT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NVCT?

    Nuvectis pharma, inc. (NVCT)'s Free Cash Flow (FCF) for the period is -3.97M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 61.22% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NVCT?

    The latest valuation data shows Nuvectis pharma, inc. (NVCT) has a Price-To-Earnings (PE) ratio of -8.06 and a Price/Earnings-To-Growth (PEG) ratio of 0.19. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.